Sector
PharmaceuticalsOpen
₹1,111Prev. Close
₹1,112.9Turnover(Lac.)
₹2,081.19Day's High
₹1,128.75Day's Low
₹1,041.552 Week's High
₹1,335.152 Week's Low
₹611.2Book Value
₹199.45Face Value
₹2Mkt Cap (₹ Cr.)
12,807.31P/E
28.66EPS
36.47Divi. Yield
2.15The sale will be conducted through the stock exchange mechanism, adhering to applicable legal requirements.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 24.51 | 24.51 | 24.51 | 1.96 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,307.82 | 2,113.7 | 2,029.81 | 750.79 |
Net Worth | 2,332.33 | 2,138.21 | 2,054.32 | 752.75 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 |
---|---|
Revenue | 1,885.16 |
yoy growth (%) | |
Raw materials | -905.49 |
As % of sales | 48.03 |
Employee costs | -149.13 |
Y/e 31 Mar( In .Cr) | Mar-2021 |
---|---|
Profit before tax | 470.94 |
Depreciation | -33.39 |
Tax paid | -119.36 |
Working capital | |
Other operating items |
Y/e 31 Mar | Mar-2021 |
---|---|
Growth matrix (%) | |
Revenue growth | |
Op profit growth | |
EBIT growth | |
Net profit growth |
Particulars (Rupees in Crores.) | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|
Gross Sales | 1,885.17 | 1,537.31 | 886.42 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 1,885.17 | 1,537.31 | 886.42 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 0.81 | 11.99 | 0.44 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,887.55 | 162.64 | 4,52,670.53 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,817.95 | 93.02 | 1,54,512 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,510.35 | 30.73 | 1,22,039.52 | 1,055.94 | 0.86 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.65 | 75.14 | 1,12,925.71 | 469 | 0.84 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,662.4 | 26.98 | 1,11,144.22 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director & CEO
Yasir Yusufali Rawjee
Executive Director
Vinod Naik
Independent Non Exe. Director
Manju Agarwal
Independent Non Exe. Director
Taruvai Laxminarayanan Easwar
Chairman (Non-Executive)
HIREN KARSANBHAI PATEL
Independent Director
KAUSHIKBHAI NANDUBHAI PATEL
Independent Director
VIJAYKUMAR RATILAL SHAH
Independent Director
Savan Godialwala
Company Sec. & Compli. Officer
Rudalf Corriea
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Glenmark Life Sciences Ltd
Summary
Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited, on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited dated 10 August 2018. A shareholders resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKlines (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankle
Read More
The Glenmark Life Sciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1045.25 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Life Sciences Ltd is ₹12807.31 Cr. as of 22 Oct ‘24
The PE and PB ratios of Glenmark Life Sciences Ltd is 28.66 and 5.49 as of 22 Oct ‘24
The 52-week high/low is the highest and lowest price at which a Glenmark Life Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glenmark Life Sciences Ltd is ₹611.2 and ₹1335.1 as of 22 Oct ‘24
Glenmark Life Sciences Ltd's CAGR for 5 Years at 6.91%, 3 Years at 19.14%, 1 Year at 68.85%, 6 Month at 24.50%, 3 Month at 22.91% and 1 Month at -8.00%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice